Regorafenib analogues and their ferrocenic counterparts: synthesis and biological evaluation - Archive ouverte HAL
Article Dans Une Revue New Journal of Chemistry Année : 2020

Regorafenib analogues and their ferrocenic counterparts: synthesis and biological evaluation

Myron Wilde

Résumé

Approved by the FDA in 2012, regorafenib is one of the last chance treatments for colorectal cancer. While various analogues have already been prepared, ferrocenic derivatives have never been evaluated. In this study, we prepared various ferrocene-containing derivatives of regorafenib and recorded their biological activity in kinase and cellular assays. This led to the identification of a squaramide derivative which shows a good cellular activity and three ferrocene analogues with promising activity in both kinase and cellular assays.

Domaines

Chimie
Fichier principal
Vignette du fichier
Wilde-2020-Regorafenib analogues and their ferrocenic counterparts synthesis .pdf (1.5 Mo) Télécharger le fichier
Ferrocene analogues regorafenib - ESI - HAL.pdf (7.65 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03100285 , version 1 (21-01-2021)

Identifiants

Citer

Myron Wilde, Danielle Arzur, Blandine Baratte, Dorian Lefebvre, Thomas Robert, et al.. Regorafenib analogues and their ferrocenic counterparts: synthesis and biological evaluation. New Journal of Chemistry, 2020, 44 (45), pp.19723-19733. ⟨10.1039/d0nj05334a⟩. ⟨hal-03100285⟩
116 Consultations
128 Téléchargements

Altmetric

Partager

More